JP2018538335A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018538335A5 JP2018538335A5 JP2018532639A JP2018532639A JP2018538335A5 JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5 JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018532639 A JP2018532639 A JP 2018532639A JP 2018538335 A5 JP2018538335 A5 JP 2018538335A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf15
- therapeutic agent
- seq
- conjugate
- hgdf15
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562270967P | 2015-12-22 | 2015-12-22 | |
| US62/270,967 | 2015-12-22 | ||
| PCT/IB2016/057839 WO2017109706A1 (en) | 2015-12-22 | 2016-12-20 | Methods of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018538335A JP2018538335A (ja) | 2018-12-27 |
| JP2018538335A5 true JP2018538335A5 (https=) | 2020-01-30 |
| JP6946304B2 JP6946304B2 (ja) | 2021-10-06 |
Family
ID=57796765
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018532639A Expired - Fee Related JP6946304B2 (ja) | 2015-12-22 | 2016-12-20 | 増殖分化因子１５（ｇｄｆ−１５）を使用して代謝障害を処置するまたは軽快させる方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20190000923A1 (https=) |
| EP (1) | EP3393494A1 (https=) |
| JP (1) | JP6946304B2 (https=) |
| CN (1) | CN108367053A (https=) |
| WO (1) | WO2017109706A1 (https=) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2694092B1 (en) | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| AU2015296640B2 (en) | 2014-07-30 | 2020-05-21 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US10004596B2 (en) | 2014-07-31 | 2018-06-26 | Lensgen, Inc. | Accommodating intraocular lens device |
| EP3701969A1 (en) | 2014-10-31 | 2020-09-02 | NGM Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| SMT202100230T1 (it) * | 2015-10-23 | 2021-07-12 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Molecole di legame che inibiscono la crescita tumorale |
| KR102433503B1 (ko) | 2016-05-24 | 2022-08-18 | 노보 노르디스크 에이/에스 | Mic-1 화합물 및 이것의 사용 |
| JP2020502056A (ja) * | 2016-11-13 | 2020-01-23 | イマジン ファーマ | 糖尿病、高血圧および高コレステロール血症を治療するための組成物および方法 |
| TWI710377B (zh) * | 2017-05-23 | 2020-11-21 | 丹麥商諾佛 儂迪克股份有限公司 | Ｍｉｃ－１化合物及其用途 |
| CN111163795A (zh) | 2017-09-10 | 2020-05-15 | 诺沃挪第克公司 | 用于治疗肥胖症的mic-1和glp-1 |
| TWI724392B (zh) * | 2018-04-06 | 2021-04-11 | 美商美國禮來大藥廠 | 生長分化因子15促效劑化合物及其使用方法 |
| CR20200510A (es) | 2018-04-09 | 2020-11-26 | Amgen Inc | Protreínas de fusión del factor de diferenciación de crecimiento 15 |
| US12508306B2 (en) | 2018-04-25 | 2025-12-30 | Washington University | Compositions and methods of use thereof for treatment of metabolic diseases and related disorders |
| EP3833974A2 (en) | 2018-08-10 | 2021-06-16 | Novartis AG | Gfral extracellular domains and methods of use |
| EA202191105A1 (ru) | 2018-10-22 | 2021-08-03 | Янссен Фармацевтика Нв | Слитые белки, полученные из глюкагоноподобного пептида 1 (glp1) и ростового фактора дифференцировки 15 (gdf15), и их применение |
| EP3883960A4 (en) * | 2018-11-20 | 2022-11-09 | Janssen Pharmaceutica NV | GDF15 ANALOGUES AND METHODS OF USE TO REDUCE BODY WEIGHT AND/OR REDUCING FOOD INTAKE |
| US20220098252A1 (en) | 2019-01-25 | 2022-03-31 | Ospedale San Raffaele S.R.L. | Inhibitor of dux4 and uses thereof |
| PE20220500A1 (es) * | 2019-04-23 | 2022-04-07 | Lg Chemical Ltd | POLIPEPTIDO DE FUSION QUE COMPRENDE LA REGION Fc DE INMUNOGLOBULINA Y GDF15 |
| EP4041281B1 (en) | 2019-10-04 | 2025-11-26 | Amgen Inc. | Use of gdf15 for treating cardiometabolic syndrome and other conditions |
| EP4085077A4 (en) | 2019-12-31 | 2024-01-17 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of glp-1 and gdf15 and conjugates thereof |
| WO2021139763A1 (zh) * | 2020-01-08 | 2021-07-15 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| CN111333505B (zh) * | 2020-03-31 | 2022-07-26 | 东莞市东阳光生物药研发有限公司 | 制备长链脂肪二酸单苄酯的方法及其应用 |
| EP4237438A4 (en) | 2020-10-27 | 2024-11-27 | Beijing QL Biopharmaceutical Co., Ltd. | GDF15 FUSION PROTEINS AND THEIR USE |
| KR102569644B1 (ko) * | 2020-10-30 | 2023-08-23 | 가톨릭대학교 산학협력단 | Gdf15를 유효성분으로 함유하는 면역질환의 예방 및 치료용 조성물 |
| WO2022219495A1 (en) | 2021-04-12 | 2022-10-20 | Novartis Ag | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| CN117750968A (zh) | 2021-05-21 | 2024-03-22 | 株式会社柳韩洋行 | 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物 |
| CA3219645A1 (en) * | 2021-05-21 | 2022-11-24 | Yuhan Corporation | Composition for combination therapy comprising growth differentiation factor-15 variant and glucagon-like peptide-1 receptor agonist |
| EP4476212A1 (en) | 2022-02-10 | 2024-12-18 | Novartis AG | 2-((4-((s)-2-(4-chloro-2-fluorophenyl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-imidazole derivatives as activators of the glp1 receptor for the treatment of obesity |
| WO2023154953A1 (en) | 2022-02-14 | 2023-08-17 | Ngm Biopharmaceuticals, Inc. | Gdf15 polypeptides for treating and preventing autoimmune diseases |
| EP4389762A1 (en) | 2022-12-23 | 2024-06-26 | Ospedale San Raffaele S.r.l. | Inhibitors of dux4 activity and their use in therapy. |
| CN118995820A (zh) * | 2024-10-22 | 2024-11-22 | 江苏凯基生物技术股份有限公司 | 一种生长分化因子-15及其制备方法 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
| ATE92107T1 (de) | 1989-04-29 | 1993-08-15 | Delta Biotechnology Ltd | N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen. |
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| ES2324433T3 (es) | 1995-06-22 | 2009-08-06 | St Vincent's Hospital Sydney Limited | Tgf-beta novedoso similar a citocina. |
| JP4588808B2 (ja) * | 1996-11-01 | 2010-12-01 | 塩野義製薬株式会社 | ヒト疾患モデルマウス |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| EP2213743A1 (en) | 2000-04-12 | 2010-08-04 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| WO2002085923A2 (en) | 2001-04-19 | 2002-10-31 | The Scripps Research Institute | In vivo incorporation of unnatural amino acids |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| IL161677A0 (en) | 2001-11-08 | 2004-09-27 | Protein Design Labs | Stable liquid pharmaceutical formulation of igg antibodies |
| TW200303742A (en) | 2001-11-21 | 2003-09-16 | Novartis Ag | Organic compounds |
| WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| CA2525764C (en) | 2003-05-20 | 2012-07-17 | Novartis Ag | N-acyl nitrogen heterocycles as ligands of peroxisome proliferator-activated receptors |
| BR122019021416A2 (https=) | 2003-09-19 | 2019-12-21 | ||
| HUE027902T2 (en) | 2004-02-09 | 2016-11-28 | Human Genome Sciences Inc Corp Service Company | Albumin fusion proteins |
| US8431558B2 (en) | 2004-11-01 | 2013-04-30 | The Regents Of The University Of California | Compositions and methods for modification of biomolecules |
| US8476239B2 (en) | 2005-12-20 | 2013-07-02 | Bristol-Myers Squibb Company | Stable protein formulations |
| CA2722829A1 (en) * | 2008-05-06 | 2009-11-12 | F. Hoffmann-La Roche Ag | Animal model for diabetes |
| WO2010048582A1 (en) | 2008-10-24 | 2010-04-29 | Irm Llc | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| AU2012212047A1 (en) * | 2011-02-03 | 2013-08-22 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| EP2694092B1 (en) * | 2011-04-08 | 2017-01-04 | Amgen Inc. | Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15) |
| MX360979B (es) * | 2011-09-16 | 2018-11-22 | Galectin Therapeutics Inc | Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico. |
| EP3683228A3 (en) * | 2012-01-26 | 2020-07-29 | Amgen Inc. | Growth differentiation factor 15 (gdf-15) polypeptides |
| CA2862516C (en) | 2012-03-27 | 2023-02-14 | Ngm Biopharmaceuticals, Inc. | Compositions and methods of use for treating metabolic disorders |
| US9161966B2 (en) | 2013-01-30 | 2015-10-20 | Ngm Biopharmaceuticals, Inc. | GDF15 mutein polypeptides |
| KR101993714B1 (ko) * | 2013-01-30 | 2019-06-28 | 엔지엠 바이오파마슈티컬스, 아이엔씨. | 대사 장애를 치료하는데 이용하기 위한 조성물과 방법 |
| US9862752B2 (en) | 2013-07-31 | 2018-01-09 | Amgen Inc. | Growth differentiation factor 15 (GDF-15) constructs |
| AU2015276800B2 (en) * | 2014-06-20 | 2021-03-04 | Aveo Pharmaceuticals, Inc. | Treatment of chronic kidney disease and other renal dysfunction using a GDF15 modulator |
| SG11201609706VA (en) | 2014-06-23 | 2017-01-27 | Novartis Ag | Site specific protein modifications |
| EP3157947A1 (en) | 2014-06-23 | 2017-04-26 | Novartis AG | Hsa-gdf-15 fusion polypeptide and use thereof |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| RU2017101436A (ru) | 2014-06-24 | 2018-07-24 | Ново Нордиск А/С | Mic-1 слитные белки и их применение |
| US20170334971A1 (en) | 2014-12-22 | 2017-11-23 | Novo Nordisk A/S | Alpha-1-Antitrypsin (A1AT) Fusion Proteins and Uses Thereof |
-
2016
- 2016-12-20 JP JP2018532639A patent/JP6946304B2/ja not_active Expired - Fee Related
- 2016-12-20 CN CN201680075098.4A patent/CN108367053A/zh active Pending
- 2016-12-20 EP EP16826174.1A patent/EP3393494A1/en not_active Withdrawn
- 2016-12-20 WO PCT/IB2016/057839 patent/WO2017109706A1/en not_active Ceased
- 2016-12-20 US US16/064,054 patent/US20190000923A1/en not_active Abandoned
-
2022
- 2022-04-14 US US17/720,555 patent/US20220249614A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018538335A5 (https=) | ||
| US12370262B2 (en) | Messenger RNA vaccines and uses thereof | |
| JP6715325B2 (ja) | ｓｉＲＮＡ、ｓｉＲＮＡを含む医薬組成物及び結合体、並びにそれらの応用 | |
| JP5185813B2 (ja) | 癌免疫治療のための組成物および方法 | |
| CN1139385C (zh) | 用于脂化亲水分子的方法和组合物 | |
| TWI685347B (zh) | 用於在活體中遞送ＲＮＡｉ觸發子至腫瘤細胞之聚結合物 | |
| CN103491982B (zh) | 具有酶敏感性连接的多核苷酸体内递送偶联物 | |
| JP2011530599A5 (https=) | ||
| JP2016535009A5 (https=) | ||
| WO2007030375A3 (en) | Lysosomal acid lipase therapy for nafld and related diseases | |
| EP4171574A1 (en) | Compositions and methods for inducing an immune response against coronavirus | |
| JP2026510392A (ja) | 遺伝子編集においてならびにワクチン及び治療剤として使用するためのコードｒｎａ分子を含む脂質ナノ粒子 | |
| ES2981281T3 (es) | Composiciones y métodos para modificar la superficie de las células y métodos de uso | |
| ES2220451T3 (es) | Tratamiento de una infeccion intracelular. | |
| US20100184831A1 (en) | Materials and Complexes for the Delivery of Biologically-Active Materials to Cells | |
| WO2025128871A2 (en) | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents | |
| AU2019381809B2 (en) | Compositions and uses of vasoactive intestinal peptide (VIP) antagonists | |
| JP2022188783A (ja) | 腫瘍融解ウイルスを含有する生体由来の細胞外小胞 | |
| JPWO2008075706A1 (ja) | 間質性肺炎治療剤 | |
| KR20210151062A (ko) | 히알루로난 접합체 및 이의 용도 | |
| CN101119743B (zh) | 免疫增强剂 | |
| HK1188947A (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages | |
| HK1188947B (en) | In vivo polynucleotide delivery conjugates having enzyme sensitive linkages |